Source: Virtual Congress 2020 – Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Shvets (Ivano-Frankivsk, Ukraine), M. Ostrovskyy (Ivano-Frankivsk, Ukraine), I. Savelikhina (Ivano-Frankivsk, Ukraine), O. Varunkiv (Ivano-Frankivsk, Ukraine), G. Korzh (Ivano-Frankivsk, Ukraine), K. Ostrovska (Ivano-Frankivsk, Ukraine). Markers of resistance to corticosteroids therapy in patients with pulmonary sarcoidosis. 1088

Member's Comments

No comment yet.

Related content which might interest you: Safety of corticosteroid therapy in patients with pulmonary sarcoidosis Source: International Congress 2017 – The many faces of sarcoidosis Year: 2017 Inhaled treprostinil therapy in patients with pulmonary hypertension and parenchymal lung disease Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 Pulmonary and systemic inflammatory response in patients with pulmonary infections receiving long-term glucocorticoid therapy Source: Eur Respir J 2002; 20: Suppl. 38, 15s Year: 2002 Inhaled corticosteroids and the risk of a first exacerbation in COPD patients Source: Eur Respir J 2004; 23: 692-697 Year: 2004 Pulse therapy of corticosteroids in idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010 The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis Year: 2021 Inhaled antibiotic therapy in patients with severe asthma Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Effects of oral dual ERA therapy on pulmonary function testing and 6MWT in patients with idiopathic pulmonary fibrosis and pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH Year: 2012 Long-term response to prednisone in newly treated patients with pulmonary sarcoidosis Source: Virtual Congress 2021 – Better understanding of sarcoidosis: new keys Year: 2021 The effect of augmentation therapy on systemic and pulmonary inflammation markers in α1-antitrypsin deficiency patients Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 Combination treatment with nintedanib and prednisolone for patients with idiopathic pulmonary fibrosis Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Compliance with nebulized therapy in patients with chronic lung disease Source: Eur Respir J 2001; 18: Suppl. 33, 59s Year: 2001 Response to PAH specific therapy in systemic sclerosis patients with extensive parenchymal changes and pulmonary hypertension Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Treatment failure of hospitalized patients with COPD exacerbation using systemic corticosteroids plus antibiotics: Role of early inflammatory predictors Source: International Congress 2014 – Asthma and COPD management Year: 2014 Effects of pulmonary rehabilitation on systemic and pulmonary inflammation in COPD patients Source: Annual Congress 2010 - Exercise in COPD Year: 2010 Influence of inhaled bronchodilator therapy on bacterioexcretion and LQ in patients with pulmonary TB infection with concomitant broncho-obstructive syndrome Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Pulmonary function test changes after cessation of inhaled corticosteroid therapy in asthma patients Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012 Evolution of systemic response in patients with pulmonary sarcoidosis of different course of the disease during anti-inflammatory treatment Source: Annual Congress 2009 - Sarcoidosis in review Year: 2009 Effects of pulmonary rehabilitation on systemic inflammation in patients with advanced COPD Source: Eur Respir J 2005; 26: Suppl. 49, 721s Year: 2005 Rituximab in the treatment of refractory pulmonary sarcoidosis Source: Eur Respir J 2014; 43: 1525-1528 Year: 2014